The company has a product for blood biomarker testing. Customers demand this type of product and several contacts have already been made with vital institutions in Denmark. Sales for professional use are commenced in 2020.
Here you will find the share information for Qlife Holding AB. Our press releases and financial quarterly reports, our annual reports, calendar and information about our corporate governance work. Qlife Holding AB aims for a fast and transparent accounting to shareholders and the financial market.
The company is listed on Nasdaq, First North Growth Market, Stockholm as from March 2, 2020
The Egoo product is a platform for accurate bio-marker testing. At a low cost and with equipment easy to use, it measures and analyses the patient’s blood. The patient can do the testing at home themselves. Read more on our product page.
If you have any questions, please send us a message.
In less than four minutes, CEO Thomas Warthoe explains what Egoo Health is all about, how it works and why it makes a difference for ordinary people, medical staff and health institutions.
FINANCIAL SUMMARY - FOURTH QUARTER 2020
“It is of great importance for Qlife to get a significant order from a highly professional customer directly after the CE-marking.
The Danish Patent Office has granted Qlife patent number DK180348 B1 for its biomarker detection unit.
The current CE-mark applies to the professional use of the test platform Egoo.Health for sale on the European market.
Qlife expects to CE mark its COVID-19 test for professional use in the Egoo.Health system within short.
Since May 2020, Qlife has been handling all testing for COVID-19 for professional football in Denmark.
On November 13, Qlife was informed that the Danish Medicines Agency (Lægemiddelstyrelsen) had rejected the application for temporay approval in Denmark “in the interest of health protection” for th
”We will do our utmost to protect the participating players against the coronavirus”, says Frank Smith, Covid-19 Officer, European Handball Federation Euro 2020 “It requires testing with high preci
Resolution on (A) employee option program; and (B) directed issue of warrants and approval of transfer of warrants